LONDON - AstraZeneca's rare disease unit Alexion announced on Nov. 16 that the U.S. Food and Drug Administration approved Klygefa for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Known chemically as gefurulimab, it is the first dual-binding nanobody C5 inhibitor approved in the U.S. for once-weekly subcutaneous self-administration via autoinjector.
Phase 3 Trial Shows Rapid Functional Gains by Week 26
The approval draws on the global Phase 3 PREVAIL trial, which enrolled 260 patients across 113 sites in 20 countries. At week 26, Klygefa met its primary endpoint by improving daily living scores by 1.6 points compared with placebo, with clinical gains appearing as early as week one. The rare autoimmune disorder affects an estimated 98,500 people in the U.S., including 81,000 who are antibody-positive.
"In the PREVAIL Phase III trial, gefurulimab achieved both, delivering rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection," trial investigator Kelly Gwathmey said in an AstraZeneca press release.
Safety Boxed Warning Requires Prior Meningococcal Vaccination
The therapy was generally well-tolerated, with common adverse events including injection site reactions at 12%, back pain at 8%, and vomiting at 5%. Because C5 inhibition elevates infection risk, Klygefa carries a boxed warning for serious meningococcal infections and requires vaccination at least two weeks before the first dose. Already approved in the European Union and Japan, Klygefa remains under regulatory review in China.



